Australia markets closed

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.47-0.67 (-6.01%)
At close: 04:00PM EST
10.43 -0.04 (-0.38%)
After hours: 07:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 3.19B
Enterprise value 2.40B
Trailing P/E 14.10
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.75
Price/book (mrq)2.55
Enterprise value/revenue 3.97
Enterprise value/EBITDA 6.38

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-19.16%
S&P500 52-week change 3-15.73%
52-week high 315.90
52-week low 35.42
50-day moving average 311.89
200-day moving average 310.16

Share statistics

Avg vol (3-month) 31.92M
Avg vol (10-day) 32.39M
Shares outstanding 5286.1M
Implied shares outstanding 6N/A
Float 8207.71M
% held by insiders 128.76%
% held by institutions 146.92%
Shares short (14 Nov 2022) 417.8M
Short ratio (14 Nov 2022) 48.29
Short % of float (14 Nov 2022) 411.62%
Short % of shares outstanding (14 Nov 2022) 46.22%
Shares short (prior month 13 Oct 2022) 419.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 41.17%
Operating margin (ttm)55.68%

Management effectiveness

Return on assets (ttm)15.40%
Return on equity (ttm)22.54%

Income statement

Revenue (ttm)603.21M
Revenue per share (ttm)2.12
Quarterly revenue growth (yoy)1,740.60%
Gross profit (ttm)267.62M
EBITDA 353.87M
Net income avi to common (ttm)248.36M
Diluted EPS (ttm)0.79
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)868.21M
Total cash per share (mrq)3.04
Total debt (mrq)76.11M
Total debt/equity (mrq)6.09
Current ratio (mrq)9.86
Book value per share (mrq)4.38

Cash flow statement

Operating cash flow (ttm)229.74M
Levered free cash flow (ttm)132.27M